Zymeworks Inc
NASDAQ:ZYME
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.11
17.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zymeworks Inc
Wall Street
Price Targets
ZYME Price Targets Summary
Zymeworks Inc
According to Wall Street analysts, the average 1-year price target for
ZYME
is 20.85 USD
with a low forecast of 12.12 USD and a high forecast of 31.5 USD.
ZYME Last Price Targets
Zymeworks Inc
The latest public price target was made on Nov 1, 2024 by
Derek Archila
from
Wells Fargo
,
who expects
ZYME
stock to
drop by 15%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Derek Archila
Wells Fargo
|
12
USD
Downside 15% |
1 month ago
Nov 1, 2024
|
Wells Fargo Downgrades Zymeworks (ZYME) to Equal Weight
StreetInsider
|
Stephen Willey
Stifel Nicolaus
|
28
USD
Upside 98% |
1 month ago
Oct 28, 2024
|
Zymeworks (ZYME) PT Raised to $28 at Stifel
StreetInsider
|
|
Robert Burns
H.C. Wainwright
|
12
USD
Downside 15% |
2 months ago
Sep 25, 2024
|
Zymeworks price target raised to $12 from $10 at H.C. Wainwright
TheFly
|
|
Andrew Berens
H.C. Wainwright
|
10
USD
Downside 29% |
3 months ago
Sep 18, 2024
|
H.C. Wainwright Reiterates Neutral Rating on Zymeworks (ZYME)
StreetInsider
|
|
Stephen Willey
Stifel Nicolaus
|
21
USD
Upside 49% |
3 months ago
Sep 10, 2024
|
Stifel Reiterates Buy Rating on Zymeworks (ZYME)
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ZYME's stock price target?
Price Target
20.85
USD
According to Wall Street analysts, the average 1-year price target for
ZYME
is 20.85 USD
with a low forecast of 12.12 USD and a high forecast of 31.5 USD.
What is Zymeworks Inc's Revenue forecast?
Projected CAGR
19%
For the last 8 years the
compound annual growth rate for
Zymeworks Inc's revenue is
29%.
The projected
CAGR
for the next 4 years is
19%.
You don't have any saved screeners yet
